» Articles » PMID: 38346047

Therapeutic Interventions on Human Breast Cancer Xenografts Promote Systemic Dissemination of Oncogenes

Overview
Journal PLoS One
Date 2024 Feb 12
PMID 38346047
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic dissemination following successful treatment of the primary tumour remains a common cause of death. There is mounting evidence that therapeutic interventions themselves may promote development of metastatic disease. We earlier reported that cell-free chromatin particles (cfChPs) released from dying cancer cells are potentially oncogenic. Based on this observation we hypothesized that therapeutic interventions may lead to the release of cfChPs from therapy induced dying cancer cells which could be carried via the blood stream to distant organs to transform healthy cells into new cancers that would masquerade as metastasis. To test this hypothesis, we generated xenografts of MDA-MB-231 human breast cancer cells in severe combined immune-deficient mice, and using immuno-fluorescence and FISH analysis looked for cfChPs in their brain cells. We detected multiple human DNA signals representing cfChPs in nuclei of brain cells of mice which co-localized with eight human onco-proteins. No intact MDA-MB-231 cells were detected. The number of co-localizing human DNA and human c-Myc signals increased dramatically following treatment with chemotherapy, localized radiotherapy or surgery, which could be prevented by concurrent treatment with three different cfChPs deactivating agents. These results suggest that therapeutic interventions lead to the release cfChPs from therapy induced dying cancer cells carrying oncogenes and are transported via the blood stream to brain cells to potentially transform them to generate new cancers that would appear as metastases. cfChPs induced metastatic spread of cancer is preventable by concurrent treatment with agents that deactivate cfChPs.

Citing Articles

Copper Imparts a New Therapeutic Property to Resveratrol by Generating ROS to Deactivate Cell-Free Chromatin.

Khanvilkar S, Mittra I Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861193 PMC: 11769567. DOI: 10.3390/ph18010132.


Correction: Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.

Raghuram G, Pal K, Sriram G, Khan A, Joshi R, Jadhav V PLoS One. 2024; 19(3):e0301650.

PMID: 38547094 PMC: 10977690. DOI: 10.1371/journal.pone.0301650.


Exploiting the damaging effects of ROS for therapeutic use by deactivating cell-free chromatin: the alchemy of resveratrol and copper.

Mittra I Front Pharmacol. 2024; 15:1345786.

PMID: 38455966 PMC: 10917901. DOI: 10.3389/fphar.2024.1345786.

References
1.
Rekha M, Pal K, Bala P, Shetty M, Mittra I, Bhuvaneshwar G . Pullulan-histone antibody nanoconjugates for the removal of chromatin fragments from systemic circulation. Biomaterials. 2013; 34(27):6328-38. DOI: 10.1016/j.biomaterials.2013.05.019. View

2.
Zheng H, Jiang H . Shuttling of cellular proteins between the plasma membrane and nucleus (Review). Mol Med Rep. 2021; 25(1). PMC: 8600410. DOI: 10.3892/mmr.2021.12530. View

3.
Mittra I, Pal K, Pancholi N, Shaikh A, Rane B, Tidke P . Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. Ann Oncol. 2017; 28(9):2119-2127. DOI: 10.1093/annonc/mdx318. View

4.
Martin O, Anderson R, Narayan K, MacManus M . Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?. Nat Rev Clin Oncol. 2016; 14(1):32-44. DOI: 10.1038/nrclinonc.2016.128. View

5.
Monteran L, Ershaid N, Doron H, Zait Y, Scharff Y, Ben-Yosef S . Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. Nat Commun. 2022; 13(1):5797. PMC: 9527249. DOI: 10.1038/s41467-022-33598-x. View